Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines

Caroline L. Trotter, Mary Ramsay*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    138 Citations (Scopus)

    Abstract

    At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.

    Original languageEnglish
    Pages (from-to)101-107
    Number of pages7
    JournalFEMS Microbiology Reviews
    Volume31
    Issue number1
    DOIs
    Publication statusPublished - Jan 2007

    Keywords

    • Epidemiology
    • Europe
    • Meningococcal disease
    • Vaccine

    Fingerprint

    Dive into the research topics of 'Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines'. Together they form a unique fingerprint.

    Cite this